Efficacy and prognostic biomarker analysis of PD-1 inhibitor combined with chemotherapy in the treatment of advanced gastric cancer
10.19405/j.cnki.issn1000-1492.2025.03.021
- Author:
Xichang Fei
1
;
Yao Peng
1
;
Siyu Li
1
;
Tao Wang
1
;
Mingjun Zhang
1
Author Information
1. Dept of Oncology，The Second Affiliated Hospital of Anhui Medical University，Hefei 230601
- Publication Type:Journal Article
- Keywords:
anti-PD-1;
advanced gastric cancer;
efficacy;
adverse reactions;
prognostic biomarkers
- From:
Acta Universitatis Medicinalis Anhui
2025;60(3):540-546
- CountryChina
- Language:Chinese
-
Abstract:
Objective : To analyze the current status of anti-PD-1 combined with chemotherapy in advanced gastric cancer.
Methods:The clinical data of 120 patients with advanced gastric cancer treated with chemotherapy or anti-PD-1 plus chemotherapy were retrospectively analyzed. The efficacy [measures include objective response rate(ORR), disease control rate(DCR), and progression-free survival(PFS)]and the occurrence of adverse reactions in patients was monitored. Univariate and multivariate Cox were used to analyze the relationship between clinicopathologic data [including age, gender, body mass index(BMI), differentiation degree, and related hematological indexes], specific treatment conditions and PFS, and to analyze the influence of treatment plan and line number on the curative effect.
Results : The PFS of chemotherapy plus immunotherapy was significantly better than that of chemotherapy alone(P<0.05), and the median PFS of the two was 7.17 months(95%CI5.85-8.49) and 5.33 months(95%CI3.96-5.70), respectively. In the combination group, the overall ORR was 27.5% and DCR was 94.8%. In the chemotherapy group alone, the overall ORR was 9.7% and DCR was 69.4%.In the chemotherapy plus anti-PD-1 group, a high prognostic nutritional index(PNI) level also provided superior PFS in patients with a 47% reduction in the risk of progression versus a low PNI level [HR0.53(95%CI0.30-0.96);P<0.05]. The median PFS was 7.47 months(95%CI5.83-9.11) with a high PNI level versus 6.00 months(95%CI4.45-7.55) with a low PNI level. The overall incidence of adverse reactions of chemotherapy combined with anti-PD-1 was slightly higher than that of chemotherapy alone, and the incidence of adverse reactions of grade 3-4 was similar, within a controllable range, and could be improved after clinical treatment.
Conclusion :The efficacy of anti-PD-1 combined with chemotherapy in patients with advanced gastric cancer is better than that of chemotherapy, and the adverse reactions are controllable. In the chemotherapy plus anti-PD-1 group, patients with high PNI levels achieved a higher PFS.
- Full text:2026012318433183549PD-1抑制剂联合化疗治疗...癌疗效及预后生物标志物分析_费习昌.pdf
